Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II open-label study of TMC114/ritonavir twice daily in treatment-experienced HIV-1 infected children and adolescents
2005-006179-11Phase 2Completed
- Sponsor
- Tibotec
- Start
- Apr 2006
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of darunavir in human immunodeficiency virus infection (HIV) and Human immunodeficiency virus infection type 1, sponsored by Tibotec. Primary endpoints: Pharmacokinetics of darunavir/ritonavir (Part I primary endpoint), Safety and tolerability (Part I primary endpoint) and 1 more. Started Apr 2006; status: completed.
02
Drugs
darunavir
03
Conditions
human immunodeficiency virus infection (HIV)Human immunodeficiency virus infection type 1
Beyond the preview
Go deeper on 2005-006179-11.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-006179-11.